ENDURONYL FORTE
LOE ApproachingNDAORALTABLET
Approved
Aug 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENDURONYL FORTE is an oral tablet small-molecule NDA approved in 1961 by Abbott. The mechanism of action and specific indications are not publicly documented in available data. This legacy product represents a foundational asset in Abbott's historical portfolio.
LOE Approaching
Product approaching loss of exclusivity with low competitive pressure (30 score), indicating limited team expansion and focus on managed decline or lifecycle extension strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate limited active hiring for ENDURONYL FORTE; career opportunities are primarily in lifecycle management, regulatory maintenance, and generic transition planning. Professionals joining this product should expect focus on profitability optimization and competitive defense rather than growth initiatives.
Brand ManagerProduct Manager
Worked on ENDURONYL FORTE at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.